Design, Synthesis, Biological Evaluation, and In Silico Study of Aspirin–Sulfonamide Hybrids as Potential Anticancer Agents
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Xusheng Duan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of Tec…. Hauptthemen laut MEDLINE: Aspirin, Antineoplastic Agents, Drug Design, Sulfonamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: This study was financially supported by the National Natural Science Foundation of China (No. 22075247, 22261046), the Fundamental Research Funds for the Provi….
Abstract (Originalsprache)
Aspirin's potential as a cancer treatment had garnered significant attention over the past 50 years. Presently, researchers are focused on structurally modifying aspirin to enhance its anticancer efficacy. In this study, aspirin was employed as the parent compound, and N‐acylation of aspirin chloride with piperazine‐sulfonamide hybrids was utilized to efficiently synthesize promising anticancer agents 3 . Biological assays and structure–activity relationship analysis demonstrated that the incorporation of thiophene groups significantly enhanced the anticancer activity of aspirin. Among all eight human cancer cells treated, hybrid 3k , containing a bromothiophene structure, was the most effective against human non‐small‐cell lung cancer (A549) cells (IC 50 = 36 μM), exhibiting over 33‐fold greater toxicity than parent aspirin (IC 50 > 1200 μM) and a higher selectivity index (SI = 6). Mechanistic studies revealed that hybrid 3k induced apoptosis in A549 cells and arrested the cell cycle at the G0/G1 phase. Molecular docking analysis and COX‐2 inhibition assay indicated that hybrid 3k likely exerts its anticancer effects through the inhibition of COX‐2 protein. These findings underscore the potential of hybrid 3k as a novel therapeutic agent for non‐small‐cell lung cancer and its contribution to expanding the antitumor scope of aspirin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
- Ningxia Research Center for Natural Medicine Engineering and Technology, College of Chemistry and Chemical Engineering, Ningxia University, Yinchuan, China.
- Xinjiang Key Laboratory of New Energy and Energy Storage Technology, Xinjiang Institute of Technology, Aksu, People's Republic of China.
Förderung
- This study was financially supported by the National Natural Science Foundation of China (No. 22075247, 22261046), the Fundamental Research Funds for the Provi…
Zitieren
APA
Duan, X., Ma, X., Chen, M., Zhang, T., Sun, X., Wei, M., & Bao, X. (2025). Design, Synthesis, Biological Evaluation, and In Silico Study of Aspirin–Sulfonamide Hybrids as Potential Anticancer Agents. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70001
Vancouver
Duan X, Ma X, Chen M, Zhang T, Sun X, Wei M, et al. Design, Synthesis, Biological Evaluation, and In Silico Study of Aspirin–Sulfonamide Hybrids as Potential Anticancer Agents. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70001
BibTeX
@article{Duan2025,
author = {Duan, Xusheng and Ma, Xueqin and Chen, Mengxian and Zhang, Tenghan and Sun, Xuanrong and Wei, Mengxue and Bao, Xiaoze},
title = {Design, Synthesis, Biological Evaluation, and In Silico Study of Aspirin–Sulfonamide Hybrids as Potential Anticancer Agents},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70001}
}
EUVIMED